The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape

Urothelial carcinoma is a very common malignancy and the 6^th most common in the US (1). Patients may either present with or, most commonly, progress to advanced disease, at which point the cancer is considered incurable and treatment options aim for life prolongation, tumor response and delay of progression, as well as palliation.